Renal Cell Carcinoma

We reported in 2021 p21 & Rb truncating mutations in kidney chromophobe renal cell carcinomas with suspected implications for therapy & pathogenesis. I’m fascinated by p21 & Rb truncating mutations in bladder tumors as well. More research is needed. https://t.co/RrwEr4G0Tv (@weldeiry)

Ah! So TFE3,FH def RCC also in the ddx now? Molecular next? (@kriyer68)

1. Lessons from Melanoma: Building on PD1 backbone w/ CTLA/LAG3 (FS Hodi, @wolchokj, @MPostow) 2. What’s new in IrAE mgmt? @DrJNaidoo @CardioOncology @kreynoldsMD 3. RCC Germline Genetics: Past, Present, Future (Linehan,@KidneyCancerDoc @pearldaily) 4. @kidneycan FallAdvocacy (@MikeSerzanMD)

my rule of thumb: FLK (funny looking kidney)👉🏽always consider MITF family RCC (TFEBaltered/TFE3rearranged RCC) (@slusagar)

Not sure, prob ALK rearranged RCC in adult patient. (@mohant73870)

Could the design of CONTACT-03 have been improved with a PD-1 rather than a PD-L1? @PBarataMD shares his thoughts on this and other aspects of CONTACT-03 in our recent roundtable...https://t.co/8787qeeN80 #kidneycancer (@GUOncologyNow)

Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)

Registration is open! Join @DrVaishampayan of @UMRogelCancer as she chairs an @OncLiveSOSS Prostate/RCC in-person education and networking event on 8/1 at 6:00 PM! #SOSS Register Today: https://t.co/9ObDnxwy2r (@OncLive)

Beautiful paper from @ggebraelmd, mentored by @neerajaiims @huntsmancancer, on the heels of his fantastic presentation at #KCRS23! Whether #kidneycancer or #prostatecancer, his command of the science and literature are amazing!!! @NeliMUlrich (@montypal)

Had SBRT for RCC pancreatic mets one year ago. Some side effects, but hands down better than a whipple if it holds. Stable, fingers crossed. (@mikeeharvey)

As a patient advocate, agree we need prospective trials. Would have hoped to see #QoL as an endpoint given the potential to delay/avoid systemic toxicities for oligomet #kidneycancer patients. Hugely important for patient decision making. (@DebMaskens)

As we showcase data presented at #ASCO23, watch @DrChoueiri, of @DanaFarber, talk through the results of the CONTACT-03 trial in mRCC! @ASCO #kcsm https://t.co/QmlzC5poPO (@OncLive)

NEW KIDNEY MODEL WITH BLOOD PERFUSION 🩸 Please, take a look! @prokarurol @AntonioAlcarazA @vital_hevia @DrJM_Gaya @DrVitagliano😉 What do you think about it? #RAPN #kidneycancer #urology #surgery #partialnephrectomy https://t.co/HnzL6a3wL8 (@urotrainer)

Congratulations to the lab of @BraunMDPhD! The team has received approximately $5.75M in funding from @theNCI and @DeptofDefense to investigate the immune microenvironment of renal cell carcinoma. #RCC #kidneycancer #cancerresearch @YaleMed @SmilowCancer https://t.co/Y4ssOlviGt (@YaleCancer)

🎥@BraunMDPhD of @YaleMed discusses the unique immune biology of kidney cancer and the need for targeted studies to understand resistance and improve anti-tumor immunity: ➡️https://t.co/xvWEtPBhOk #KCSM #ASCO23 #ImmunoOnc (@VJOncology)

Amazing few days in Cuyuna, MN on a MTB trip with @BradLeibovichMD @kakeegs3 @wandering_gu My first MTB experience. And I’m hooked What a blast and thankful for great friends to spend some time with @MayoUrology @KidneyCancer @MDAndersonNews @UMichUrology @VUMCurology (@ChapinMD)

Great group for a great cause! @KidneyCancer (@kakeegs3)

Now I’m curious if this is a figure of speech or if @KidneyCancerDoc and @chrisfilson_uro will be working on perfecting their roundhouse kicks together. (@KBGinsburg)

Medical professionals give insight into new medications coming out for patients with kidney cancer, explained by @DrRanaMcKay. https://t.co/59YeE9WhOd (@cure_today)

Cabozantinib in combination with atezolizumab in non-clear cell #RCC: Extended follow-up results of cohort 10 of the #COSMIC021 study. @BradMcG04 @DanaFarber joins @PBarataMD @caseccc to discuss these results on UroToday > https://t.co/RBIepZ1r4w @ExelixisInc (@urotoday)

Comparing the cost-effectiveness of immunotherapy-based regimens and sunitinib in treating metastatic #RenalCellCarcinoma from a public payer perspective. Manish Kohli, MD @huntsmancancer joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/pKTfVnZcwj @JCOOP_ASCO (@urotoday)

According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (@OncLive)

A Predictive Model for Kidney Failure After Nephrectomy for Localized Kidney Cancer: The Kidney Cancer Risk Equation https://t.co/WOX9PwMbAN @OksanaH12 @JayNayakMD @nickgrubic @ThomasFerg28 @Msood99M @NavTangri @SevenOaksCDIC @ICESOntario (@AJKDonline)

Watch our Dr. Eric Jonasch discuss second-line treatment options for advanced clear cell renal cell carcinoma: https://t.co/xnPcaDgj40 @OncLive @Ejonasch #KidneyCancer #EndCancer (@MDAndersonNews)

Agree! No data yet support sequential IO in RCC. Safety concerns and potential toxicity make it a risky approach. More research needed to explore benefits in other treatment settings. Let's prioritize patient safety and wait for solid evidence. #RCC #ResearchMatters (@nataliagandur)

8b/16 #TumorBoardTuesday #RCC @QingZhangLab #KidneyCancer ✨TiNivo-2: 📚@DrChoueiri @AlbigesL @HHammersMD @DrRanaMcKay @DrDanielHeng @motzermd https://t.co/UbPQeV5LgU (@katy_beckermann)

Agree!. Although mutational profiles and NGS have limited utility in predicting IO and TKI resistance in clear cell RCC, ongoing research offers hope for better biomarkers. Collaborative efforts and tumor board discussions remain crucial for personalized treatment strategies.… https://t.co/d9ByKqsgzi (@nataliagandur)

🙏🏼 Thank you for an outstanding & enriching #TumorBoardTuesday session on IO refractory #RCC treatment! 🎀 Stay tuned for the Case Wrap Up 🎀 on 07/20/23. 📅 Mark your calendar for 07.25 when @marklewismd @CatherineaOC delve into differentiating midgut & PNETs. (@TumorBoardTues)

CONTACT-3 clearly shows the addition of atezolizumab to cabozantinib is no better than cabo alone in advanced renal cancer patients who have had PD on PD1 therapy. It seems to add to toxicity with no subset benefiting. (@tompowles1)

Keynote-564 has shown a DFS benefit for intermediate-high risk patients as adjuvant therapy in RCC 🔬HR0.63. This contrasts other ICI based adjuvant trials. Reasons for this are unclear, but may be due to difference in trial design (PROSPER, CM914) #ACScancerchat (@drfrankiejs)

11/16 #TumorBoardTuesday #RCC Back to our case 🔎 👨🏼‍🦳 Patient starts cabozantinib at 60mg qd 📆 3 mos ✋🏽🦶🏽G3 ⬇️dose reduce to 40mg 🩻scans: PR lasts for one year 🫁single new pulm met 🧐What treatment option do you consider next after progression of pembro/axi and cabo? (@katy_beckermann)

12/16 #TumorBoardTuesday #RCC #KidneyCancer ✨SOAR✨ 📌Prospective trial to study SBRT vs systemic therapy ☢️Radiation therapy by SBRT can provide 90% disease control rate. ‼️ENROLLMENT OPENS August ‘23‼️ 📚https://t.co/xAbOA4D8tA (@katy_beckermann)

0/16 #TumorBoardTuesday #RCC 👨🏻‍🏫Mini tweetorial 8👩🏻‍🏫 📌TKI monotherapy after prior IO 📍2L ✨Keynote-146: lenvatinib+pembro 55.8% ORR ✨CaboPoint: cabozantinib 31.7% ORR (prior IO/IO) & 25% (prior IO/TKI) 📍3L/4L ✨Tivo-3: prior IO/TKI fail, tivozanib had 24% ORR @ChungHanLee3 (@katy_beckermann)

14/16 #TumorBoardTuesday #KidneyCancer #RCC 📌VHL Syndrome 🧬Genetically inherited RCC with VHL mut 💊PO belzutifan blocks HIF: 49% ORR with time to tx response ➡️ 8 mos 🔹Loss of VHL function drives 90% of sporadic ccRCC via upregulation of HIF @VHLAlliance (@katy_beckermann)

15a/16 #TumorBoardTuesday 🧑🏼‍🔬Ongoing Trials assessing belzutifan in sporadic met #RCC ✨Pembro+lenva: https://t.co/RseK3omjaO ✨Belzu+pembro v placebo+pembro: https://t.co/UIZCuOHgoR ✨Pembro+belzu+lenva OR pembro/Quavo+lenva v pembro+lenva https://t.co/QTUdhDsyb9 (@katy_beckermann)

Agree! Approximately 70-80% of patients with renal cell carcinoma (RCC) have been found to be germline von Hippel-Lindau (VHL) mutation carriers. The VHL gene mutation is a well-known genetic alteration associated with the development of RCC. It is important to note that this… https://t.co/PbUjLe8hz2 (@nataliagandur)

15b/16 #TumorBoardTuesday #RCC #KidneyCancer 👨🏻‍🔬 An additional trials are developing HIF inhibitors ✨Ph1 AB521: https://t.co/MiZKHmXp7b (@katy_beckermann)

16/16 #TumorBoardTuesday #RCC Back to our case 🔎 👨🏼‍🦳 Starts tivozanib 🔸 Phase 3 RCT in 3rd/4th line setting vs sorafenib 👨🏼‍🦳 patient receives tivozanib 🔹 18% ORR & 5.6 mos PFS on tivozanib vs 8% ORR sorafenib & 3.9 mos PFS 🩻 Continue to see 👨🏼‍🦳 q6wk 📚 https://t.co/mJUHkCSirN (@katy_beckermann)

#TumorBoardTuesday 🤔What percentage of patients with RCC are germline VHL mutation carriers❓ (@MPishvaian)

For clarification- the 49% ORR is for patients w germline VHL mutation w a primary RCC of < 3 cm (@ClarkHenegan)

But if you have germline VHL then risk for RCC (usually Clear Cell type) is high - up to 70% (@HannahAlison20)

#TumorBoardTuesday No laughing but I keep a folder at my desk for virtual tumor board at my institution because hereditary syndrome associated with renal tumors are not common 😁 - they say germline mutations are in 5% of RCC (@HannahAlison20)